… (EF) endothelial C3 staining in arterioles from patients with CFH (E) and CFI (F) mutations.
(G) Subendothelial localization of C9 staining in an arteriole from a patient with a CFH …

Because macrophages have been implicated as major players in the mechanism of action
of rituximab, we have investigated the factors that modulate their tumor cell killing potential. …

Bleeding time, altered in most uraemic patients, may be influenced by packed cell volume (PCV).
Uraemic patients are often anaemic, so the influence of PCV on bleeding time was …

… Elisa Gotti … (E and F) Representative micrographs of transmission electron microscopy on
hBM-MSC … McDaniel LD, E Young, J Delaney, F Ruhnau, KB Ritchie and JH Paul. (2010). High …

… In (E), MLRs were conducted in the absence or in the presence of either untreated MSCs or
MSCs pre-exposed to patients' serum taken at basal (n = 3) or 7 days posttransplant (n = 3). …

Allogeneic immune responses are modulated by a subset of host T cells with regulatory
function (Treg) contained within the CD4+ CD25 high subset. Evidence exists that Treg expand …

… plasma iohexol clearance determination and obtained from the electronic database managed
at the study coordinating Clinical Research Center for Rare Diseases ‘Aldo e Cele Daccò’. …

We analyzed in B-chronic lymphocytic leukemia (B-CLL) whole blood assays the activity of
therapeutic mAbs alemtuzumab, rituximab, and type II glycoengineered anti-CD20 mAb …

… Author links open overlay panel Dario Cattaneo , Norberto Perico , Flavio Gaspari ,
Eliana Gotti , Giuseppe Remuzzi … Shipkova, VW Armstrong, E. Wieland …

… Panel (e) reports intragraft CD105 and CD44 double positive cell counts in patients 3
and 4 and in sections of normal renal tissue from patients undergoing nephrectomy for renal …